MAPT and Alzheimer disease: However, clinical criteria may be outdated, at least in AD, as recent years are witnessing a shift toward the use of pathology-derived biomarkers such as cerebrospinal fluid amyloid and phospho-tau or amyloid-PET, which yield comparably higher sensitivity and specificity (Gaugler et al., 2013).